AWM
ITRM

Apollon Wealth Management’s Iterum Therapeutics ITRM Stock Holding History

Apollon Wealth Management’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-200,000
Closed -$214K – 947
2023
Q2 		$214K Buy
+200,000
New +$221K 0.01% 849

Other funds holding ITRM

NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
KFS
Kelly Financial Services Braintree, Massachusetts $467M AUM 21.13% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
CCMW
Cypress Capital Management (Wyoming) Sheridan, Wyoming $108M AUM 54.47% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Apollon Wealth Management's ITRM Position: Q3 2023 in Review

Apollon Wealth Management sold out of Iterum Therapeutics (ITRM) in Q3 2023, closing a stake of 200,000 shares — an estimated $214K sold.

Apollon Wealth Management first reported a position in ITRM in Q2 2023 and held it in 1 quarter. The position peaked at $214K in Q2 2023. 15 funds tracked by Wall St. Rank hold ITRM as of Q3 2023.

  • Apollon Wealth Management reported no remaining Iterum Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Apollon Wealth Management sold 200,000 Iterum Therapeutics shares in Q3 2023, an estimated $214K.
  • Apollon Wealth Management first reported a position in Iterum Therapeutics in Q2 2023 and held it in 1 quarter.
  • Apollon Wealth Management's Iterum Therapeutics position peaked at $214K in Q2 2023.
  • 15 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2023.

Based on Apollon Wealth Management's 13F filing for Q3 2023, filed 14 Nov 2023.